Bi Qing Teng

Ms. Bi Qing Teng

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
SFShi Fang
Shi Fang
JWJing Wu
Jing Wu
JRJohn J. Reho
John J. Reho
KLKo-Ting Lu
Ko-Ting Lu
DBDaniel T. Brozoski
Daniel T. Brozoski
CSCurt D. Sigmund
Curt D. Sigmund
Arterial stiffness predicts cardiovascular disease and all-cause mortality, but its treatment remains challenging. Mice treated with angiotensin II (Ang II) develop hypertension, arterial stiffness, vascular dysfunction, and a downregulation of Rho-related BTB domain–containing protein 1 (RhoBTB1) in the vasculature. RhoBTB1 is associated with blood pressure regulation, but its function is poorly understood. We tested the hypothesis that restoring RhoBTB1 can attenuate arterial stiffness, hypertension, and vascular dysfunction in Ang II–treated mice. Genetic complementation of RhoBTB1 in the vasculature was achieved using mice expressing a tamoxifen-inducible, smooth muscle–specific RhoBTB1 transgene. RhoBTB1 restoration efficiently and rapidly alleviated arterial stiffness but not hypertension or vascular dysfunction. Mechanistic studies revealed that RhoBTB1 had no substantial effect on several classical arterial stiffness contributors, such as collagen deposition, elastin content, and vascular smooth muscle remodeling. Instead, Ang II increased actin polymerization in the aorta, which was reversed by RhoBTB1. Changes in the levels of 2 regulators of actin polymerization, cofilin and vasodilator-stimulated phosphoprotein, in response to RhoBTB1 were consistent with an actin depolymerization mechanism. Our study reveals an important function of RhoBTB1, demonstrates its vital role in antagonizing established arterial stiffness, and further supports a functional and mechanistic separation among hypertension, vascular dysfunction, and arterial stiffness.

28 October 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
JHJulia Hilbrands
Julia Hilbrands
MFMary Beth Feuling
Mary Beth Feuling
ASAniko Szabo
Aniko Szabo
BTBi Qing Teng
Bi Qing Teng
NFNicole Fabus
Nicole Fabus
PGPraveen S Goday
Praveen S Goday
Hospitalized, critically ill children are at increased risk of developing malnutrition. While several pediatric nutrition screening tools exist, none have been validated in the pediatric intensive care units (PICU). The Children’s Wisconsin Nutrition Screening Tool (CWNST) is a unique nutrition screening tool that includes the Pediatric Nutrition Screening Tool (PNST) and predictive elements from the electronic medical record and was found to be more sensitive than the PNST in acute care units. The aim of this study was to assess the performance of the tool in detecting possible malnutrition in critically ill children. The data analysis, including the results of the current nutrition screening, diagnosis, and nutrition status was performed on all patients admitted to PICUs at Children’s Wisconsin in 2019. All 250 patients with ≥1 nutrition assessment by a dietitian were included. The screening elements that were predictive of malnutrition included parenteral nutrition, positive PNST, and BMI-for-age/weight-for-length z-score. The current screen had a sensitivity of 0.985, specificity of 0.06, positive predictive value (PPV) of 0.249, and negative predictive value of 0.929 compared to the PNST alone which had a sensitivity of 0.1, specificity of 0.981, PPV of 0.658, and NPV of 0.749. However, of the 250 included patients, 97.2% (243) had a positive nutrition screen. The CWNST can be easily applied through EMRs and predicts the nutrition risk in PICU patients but needs further improvement to improve specificity.

1 July 2024 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
SRSeth A. Roge
Seth A. Roge
AVAndrew M. Valiquette
Andrew M. Valiquette
BTBi Qing Teng
Bi Qing Teng
KYKai Yang
Kai Yang
SGSteven I. Grindel
Steven I. Grindel

1 June 2022 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
RSRodney Sparapani
Rodney Sparapani
BTBi Qing Teng
Bi Qing Teng
JHJulia Hilbrands
Julia Hilbrands
RPRebecca Pipkorn
Rebecca Pipkorn
MFMary Beth Feuling
Mary Beth Feuling
PGPraveen S Goday
Praveen S Goday

27 November 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
CKCarlene Kranjac
Carlene Kranjac
PSPatricia Sheean
Patricia Sheean
Anjishnu BanerjeeAnjishnu Banerjee
Anjishnu Banerjee
BTBi Qing Teng
Bi Qing Teng
KOKathleen O'Connell
Kathleen O'Connell
MSMelinda Stolley
Melinda Stolley
Background/Objectives: Cancer survivors are a growing population in the United States, with projections of 22.5 million by 2030. Cancers of the prostate (PC) and breast (BC) are among the most prevalent. Despite a high burden of disease, African American survivors are underrepresented in health behavior research. Leveraging two large databases, this study uniquely characterizes dietary supplement (DS) use among African American cancer survivors to explore potential intervention points. Methods: Characteristics from 376 African American cancer survivors (130 PC; 246 BC) in lifestyle intervention trials were examined. DS use was self-reported and categorized by type. A logistic regression model examined associations between use and survivor characteristics. Results: Overall, 215 (63.80%) survivors with baseline medication log data (N = 337) reported using at least one DS, with a higher prevalence among BC survivors (67.44%) than PC survivors (57.38%). Vitamin D ± calcium combinations, multivitamins, omega-3 fatty acids, calcium, Vitamin B12, and Vitamin C were the most frequently reported. Total comorbidities (mean = 2.38, SD = 1.66) significantly predicted increased DS use among BC and PC survivors. Educational attainment (≤12th grade vs. graduate/professional education) and diet quality (high vs. low) were significantly associated with lower odds of DS use for PC survivors. Only diet quality (moderate vs. low) was significantly associated with higher odds of DS use in BC survivors. Conclusions: DS use is common among African American PC and BC survivors participating in lifestyle interventions. These findings underscore the need for evidence-based guidelines regarding DS use among cancer survivors and the need to include diverse populations.